Prostaglandins and schizophrenia: a review

Area of Science:

• Neuroscience
• Biochemistry
• Psychiatry

Background:

• Clinical observations suggest a link between schizophrenia and prostaglandin E (PGE) levels.
• Previous research has explored hypotheses of both PGE deficiency and excess in schizophrenia.

Purpose of the Study:

• To investigate the potential role of prostaglandin E (PGE) deficiency and/or excess in schizophrenia.
• To evaluate conflicting evidence regarding PGE levels in schizophrenic patients.

Main Methods:

• Comparison of ADP-induced synthesis and PGE1-stimulated cAMP accumulation in platelets of schizophrenic patients versus controls.
• Measurement of immunoreactive PGE concentrations in the cerebrospinal fluid (CSF) of schizophrenic patients, healthy controls, neurotic patients, and neurological patients.
• Assessment of the therapeutic effect of paracetamol on schizophrenia symptoms.

Main Results:

• Platelets from schizophrenic patients showed significantly lower ADP-induced synthesis and PGE1-stimulated cAMP accumulation compared to controls, suggesting PGE1 deficiency.
• Cerebrospinal fluid (CSF) PGE concentrations were higher in schizophrenic patients than in healthy, neurotic, or neurologically examined patients, supporting PGE excess.
• Paracetamol, which reduces prostaglandin levels, did not demonstrate therapeutic effects in schizophrenia.

Conclusions:

• Evidence supports both PGE1 deficiency and PGE excess hypotheses in schizophrenia.
• The two hypotheses are not directly compatible due to the complex, dose-dependent, bell-shaped response curves of prostaglandins in biological systems.
• Further research is needed to elucidate the precise role of prostaglandins in schizophrenia pathophysiology.